Investors & Media

Mark Goldberg, M.D. has served as a member of our Board of Directors since June 2015. Since 2018, Dr. Goldberg has served as an advisor at CANbridge Life Sciences Ltd., a biopharmaceutical company focused on rare diseases and rare oncology, and served as Acting Chief Medical Officer from 2015 to 2018. Previously, he served as an advisor and held various executive positions of increasing responsibility at Synageva Biopharma Corp. until its acquisition by Alexion Pharmaceuticals, Inc., including Executive Vice President, Medical and Regulatory Strategy. Earlier in his career, Dr. Goldberg served in various management capacities of increasing responsibility at Genzyme from November 1996 to July 2011, including as Senior Vice President, Clinical Development and Global Therapeutic Head, Oncology, Genetic Health, and as Chairman of the Early Product Development Board. Dr. Goldberg has been a faculty member of the Hematology Division at Brigham and Women’s Hospital since 1987 and was a staff physician at the Dana-Farber Cancer Institute from 1996 to 2018. From 1996 to 2021, Dr. Goldberg was a part-time Associate Professor of Medicine at Harvard Medical School. Dr. Goldberg currently serves as a member of the Compensation and Governance and Nominating Committees of the Board of Directors of ImmunoGen, Inc., Chair of the Nominating and Corporate Governance Committee and member of the Compensation Committee of the Board of Directors of GlycoMimetics, Inc., and on the Board of Directors of Avacta Group plc. Dr. Goldberg also serves as a member of the National Board of Directors of the American Cancer Society (ACS), the ACS Eastern New England Area Board and the ACS New England Division Board. Dr. Goldberg received an A.B. in biochemical sciences from Harvard College and an M.D. from Harvard Medical School.